Akari Therapeutics, Plc

22 Boston Wharf Road FL 7

Boston, MA 02210

 

October 25, 2023

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:	Akari Therapeutics, Plc (the “Company”)
	Registration Statement on Form F-3 (the “Registration Statement”) Filed October 20, 2023 File No. 333-275119

 

Dear Mr. Drory:

 

The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern Time on October 26, 2023, or as soon thereafter as practicable.

 

[Signature Page Follows]

 

 

	Very truly yours,
	AKARI THERAPEUTICS, PLC
	By:	/s/ Rachelle Jacques
	Name:	Rachelle Jacques
	Title:	President and Chief Executive Officer